<DOC>
	<DOCNO>NCT02326142</DOCNO>
	<brief_summary>The primary objective study ass efficacy single dose OBE001 , oral oxytocin antagonist , give 7 day delay preterm birth 7 day compare placebo .</brief_summary>
	<brief_title>A Phase 2 Study OBE001 Versus Placebo Delay Preterm Birth</brief_title>
	<detailed_description>The study multi-centre , randomise , parallel group , double-blind , placebo-controlled study pregnant woman threaten preterm labour 34^0/7 35^6/7 week gestation . The study 2 part follow : - screen day delivery ( include treatment period seven day ) - maternal neonatal follow-up period day delivery 28 day post expect term date ( 28 day post-delivery later ) . In addition , observational , safety follow-up infant 2 year evaluate developmental outcome .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Obstetric Labor , Premature</mesh_term>
	<criteria>Gestational age ( GA ) 34^0/7 35^6/7 week . Subjects symptoms preterm labour . Subjects singleton pregnancy . Foetal death utero current pregnancy previous pregnancy gestational week 24 expect high risk foetal death current pregnancy . Any contraindication mother foetus stop labour prolong pregnancy maternal foetal condition likely indicate iatrogenic delivery . Use cervical cerclage pessary situ current pregnancy . The Subject condition opinion PI constitute risk contraindication participation subject trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Premature Obstetric Labor</keyword>
	<keyword>Premature Birth</keyword>
</DOC>